Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,377 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Meta-analysis of genome-wide association studies on the intolerance of angiotensin-converting enzyme inhibitors.
Mahmoudpour SH, Veluchamy A, Siddiqui MK, Asselbergs FW, Souverein PC, de Keyser CE, Hofman A, Lang CC, Doney AS, Stricker BH, de Boer A, Maitland-van der Zee AH, Palmer CN; PREDICTION-ADR consortium. Mahmoudpour SH, et al. Among authors: de keyser ce, de boer a. Pharmacogenet Genomics. 2017 Mar;27(3):112-119. doi: 10.1097/FPC.0000000000000264. Pharmacogenet Genomics. 2017. PMID: 28030426 Free PMC article.
Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors.
Maitland-van der Zee AH, Klungel OH, Stricker BH, Monique Verschuren WM, Kastelein JJ, Leufkens HG, de Boer A. Maitland-van der Zee AH, et al. Among authors: de boer a. Atherosclerosis. 2002 Aug;163(2):213-22. doi: 10.1016/s0021-9150(01)00725-0. Atherosclerosis. 2002. PMID: 12052467 Review.
The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype.
Maitland-van der Zee AH, Stricker BH, Klungel OH, Kastelein JJ, Hofman A, Witteman JC, Breteler MM, Leufkens HG, van Duijn CM, de Boer A. Maitland-van der Zee AH, et al. Among authors: de boer a. Pharmacogenetics. 2002 Nov;12(8):647-53. doi: 10.1097/00008571-200211000-00009. Pharmacogenetics. 2002. PMID: 12439225
Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes.
Maitland-van der Zee AH, Stricker BH, Klungel OH, Mantel-Teeuwisse AK, Kastelein JJ, Hofman A, Leufkens HG, van Duijn CM, de Boer A. Maitland-van der Zee AH, et al. Among authors: de boer a. Pharmacogenetics. 2003 Apr;13(4):219-23. doi: 10.1097/00008571-200304000-00006. Pharmacogenetics. 2003. PMID: 12668918
Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men.
Maitland-van der Zee AH, Klungel OH, Stricker BH, Veenstra DL, Kastelein JJ, Hofman A, Witteman JC, Leufkens HG, van Duijn CM, de Boer A. Maitland-van der Zee AH, et al. Among authors: de boer a. Pharmacogenetics. 2004 Jan;14(1):53-60. doi: 10.1097/00008571-200401000-00006. Pharmacogenetics. 2004. PMID: 15128051
1,377 results